INS and type 1 diabetes mellitus: As a proof‐of‐concept study in vivo, we decided to target T1D, a highly prevalent chronic disease.[42] Initially, we used the Sleeping Beauty transposase system[43] to establish a monoclonal cell line in which the switch components for regulating the expression of both mouse insulin and SEAP (Figure S6a, Supporting Information) were stably integrated into the genome of HEK‐293T cells.